Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutism

被引:15
|
作者
Venturoli, S [1 ]
Paradisi, R [1 ]
Bagnoli, A [1 ]
Colombo, FM [1 ]
Ravaioli, B [1 ]
Vianello, F [1 ]
Mancini, F [1 ]
Gualerzi, B [1 ]
Porcu, E [1 ]
Seracchioli, R [1 ]
机构
[1] Univ Bologna, Clin Ostetr & Ginecol, Dept Gynecol & Obstet, Reprod Med Unit, I-40138 Bologna, Italy
关键词
antiandrogens; hirsutism; hyperadrogenism;
D O I
10.1159/000048086
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the safety and efficacy of a low dose of flutamide (125 mg/day) in maintaining the clinical results already obtained using a higher dose (250 mg/day), in women suffering from hirsutism. Method: Forty-three women suffering from hirsutism of varying origin received 250 mg/day of flutamide as an initial treatment for 12 months and, subsequently, 125 mg/day of flutamide for an additional 12 months as a maintenance treatment. Hirsutism was evaluated by the Ferriman-Gallwey score, and hair diameter and hair growth rate were determined by a special image analysis processor. Biochemical, clinical and hormonal parameters were evaluated in basal conditions and every 2-6 months. Results: The significant decrease in the hirsutism score, hair diameter and hair growth rate during the initial treatment period was confirmed at the end of the maintenance treatment period. Androgen levels decreased up to the end of the initial treatment period and partially decreased during the maintenance treatment. During the initial treatment period, 4 subjects showed an increase of aspartate aminotransferase and alanine aminotransferase and dropped out. During the maintenance treatment period, no side effects or complications were observed. Conclusion: Satisfactory management of hirsutism with flutamide seems to be represented by an initial treatment period using 250 mg/day to achieve satisfactory results, followed by a long maintenance treatment period using 125 mg/day. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 50 条
  • [31] Clinical experience with ultra low-dose amiodarone (100 mg/day).
    Tanzi, MG
    Schoen, MD
    Bauman, JL
    PHARMACOTHERAPY, 2002, 22 (10): : 1327 - 1327
  • [32] A comparison between two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism
    Muderris, II
    Bayram, F
    Sahin, Y
    Kelestimur, F
    FERTILITY AND STERILITY, 1997, 68 (04) : 644 - 647
  • [33] LOW-DOSE PUVA MAINTENANCE IN PSORIASIS FOLLOWING INGRAM THERAPY
    VANDEKERKHOF, PCM
    MALI, JWH
    BRITISH JOURNAL OF DERMATOLOGY, 1981, 104 (06) : 681 - 684
  • [34] LOW-DOSE AMINOGLUTETHIMIDE (125 MG TWICE DAILY) WITH HYDROCORTISONE FOR THE TREATMENT OF ADVANCED POSTMENOPAUSAL BREAST-CANCER
    HARRIS, AL
    CANTWELL, BMJ
    SAINSBURY, JR
    NEEDHAM, G
    EVANS, RGB
    DAWES, PJDK
    WILSON, R
    FARNDON, J
    BREAST CANCER RESEARCH AND TREATMENT, 1986, 7 : 41 - 44
  • [35] New alternative treatment in hirsutism:: bicalutamide 25 mg/day
    Müderris, II
    Bayram, F
    Özçelik, B
    Güven, M
    GYNECOLOGICAL ENDOCRINOLOGY, 2002, 16 (01) : 63 - 66
  • [36] Clinical Efficacy of Low Dose Flutamide plus Diane-35 in the Treatment of Idiopathic Hirsutism and Polycystic Ovary Syndrome
    Boztosun, Abdullah
    Acmaz, Gokhan
    Ozturk, Ahmet
    Muderris, Iptisam Ipek
    GINEKOLOGIA POLSKA, 2013, 84 (04) : 258 - 262
  • [37] LOW-DOSE ARA-C AS MAINTENANCE TREATMENT IN AML
    CATALANO, L
    FONTANA, R
    SELLERI, C
    DEROSA, G
    ROTOLI, B
    HAEMATOLOGICA, 1989, 74 (04) : 412 - 413
  • [38] Very low dose of flutamide in the treatment of hyperandrogenism
    Fulghesu, Anna Maria
    Melis, Federica
    Murru, Giulia
    Canu, Elena
    Melis, Gian Benedetto
    GYNECOLOGICAL ENDOCRINOLOGY, 2018, 34 (05) : 394 - 398
  • [39] A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism
    Müderris, II
    Bayram, F
    Güven, M
    FERTILITY AND STERILITY, 2000, 73 (05) : 984 - 987
  • [40] Low-dose doxepin (3 and 6 mg) for the treatment of insomnia
    Lankford, Alan
    FUTURE NEUROLOGY, 2011, 6 (02) : 143 - 154